tirzepatide 16mg – Wellness at Century City regular virtual check Microdosing Tirzepatide Program | No

#ObesityManagement #Semaglutide #Wegovy #HealthcareInnovation #Pharma #PatientCare To view or add a comment, sign in MetaVia's obesity treatment candidate DA-1726 demonstrates weight loss and glycemic control in Phase 1 study MetaVia, an affiliate of Dong-A ST, reported on January 6 that its Phase 1 clinical trial evaluating the maximum tolerated dose of DA-1726(development code), a glucagon-like peptide 1(GLP-1)/glucagon(GCG) dual agonist under development for the treatment of obesity, demonstrated excellent outcomes, including pronounced weight loss, improvements in glycemic control, and a decrease in liver stiffness

Myung SK et al

They can diagnose and treat any health conditions that may be contributing to weight gain, such as thyroid disorders

Therefore, a clinical approach is needed to alleviate the progression of CKD worldwide